President and Chief Operating Officer · Bicara Therapeutics Inc. (BCAX)

Ryan Cohlhepp

A named executive officer of Bicara Therapeutics in every fiscal year CompBrief holds from FY2024 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$858,400

FY2024: $4,467,589

Compensation figures as of the proxy filed April 27, 2026 (DEF 14A).

Ryan Cohlhepp compensation by year

Bicara Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Bicara Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024FY2025
Salary$517,500$588,000
Bonus$278,000$10,000
Stock awards$0$0
Option awards$3,641,839$0
Non-equity incentive$10,000$249,900
Pension and deferred compensation$0$0
All other$20,250$10,500
Total$4,467,589$858,400

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Bicara Therapeutics Inc. DEF 14A filed April 27, 2026, accession 0001628280-26-027320, and prior-year filings. Open the filing on EDGAR.

$4.5M
$858K
FY24
FY25
SalaryBonusNon-equity incentiveOption awardsAll other

Bicara Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Claire MazumdarChief Executive Officer$927,688
Ryan Cohlhepp · this pagePresident and Chief Operating Officer$858,400
David RabenChief Medical Officer$709,164

The full Bicara Therapeutics compensation record

free company brief

This page is one person within Bicara Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Bicara Therapeutics's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Bicara Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy